CSTL News

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Cadillac Mines Appoints Pierre Beaudoin to Board of Directors

Castle Biosciences to Open New Laboratory Facility in Scottsdale

New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus

JAAD Publication Shows Improved Performance of DecisionDx®-SCC

SciBase receives additional order from Castle Biosciences, advancing the collaboration

SciBase receives additional order from Castle Biosciences, advancing the collaboration